Secretoneurin Is an Endogenous Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor That Attenuates Ca2+-Dependent Arrhythmia

Show full item record



Permalink

http://hdl.handle.net/10138/303977

Citation

Ottesen , A H , Carlson , C R , Eken , O S , Sadredini , M , Myhre , P L , Shen , X , Dalhus , B , Laver , D R , Lunde , P K , Kurola , J , Lunde , M , Hoff , J E , Godang , K , Sjaastad , I , Pettila , V , Stridsberg , M , Lehnart , S E , Edwards , A G , Lunde , I G , Omland , T , Stokke , M K , Christensen , G , Rosjo , H & Louch , W E 2019 , ' Secretoneurin Is an Endogenous Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor That Attenuates Ca2+-Dependent Arrhythmia ' , Circulation. Arrhythmia and electrophysiology , vol. 12 , no. 4 , 007045 . https://doi.org/10.1161/CIRCEP.118.007045

Title: Secretoneurin Is an Endogenous Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor That Attenuates Ca2+-Dependent Arrhythmia
Author: Ottesen, Anett H.; Carlson, Cathrine R.; Eken, Olav Sovik; Sadredini, Mani; Myhre, Peder L.; Shen, Xin; Dalhus, Bjorn; Laver, Derek R.; Lunde, Per Kristian; Kurola, Jouni; Lunde, Marianne; Hoff, Jon Erik; Godang, Kristin; Sjaastad, Ivar; Pettila, Ville; Stridsberg, Mats; Lehnart, Stephan E.; Edwards, Andrew G.; Lunde, Ida G.; Omland, Torbjorn; Stokke, Mathis K.; Christensen, Geir; Rosjo, Helge; Louch, William E.
Contributor: University of Helsinki, HUS Perioperative, Intensive Care and Pain Medicine
Date: 2019-04
Language: eng
Number of pages: 13
Belongs to series: Circulation. Arrhythmia and electrophysiology
ISSN: 1941-3149
URI: http://hdl.handle.net/10138/303977
Abstract: BACKGROUND: Circulating SN (secretoneurin) concentrations are increased in patients with myocardial dysfunction and predict poor outcome. Because SN inhibits CaMKII delta (Ca2+/calmodulin-dependent protein kinase II delta) activity, we hypothesized that upregulation of SN in patients protects against cardiomyocyte mechanisms of arrhythmia. METHODS: Circulating levels of SN and other biomarkers were assessed in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT; n=8) and in resuscitated patients after ventricular arrhythmia-induced cardiac arrest (n=155). In vivo effects of SN were investigated in CPVT mice (RyR2 [ryanodine receptor 2]-R2474S) using adeno-associated virus-9-induced overexpression. Interactions between SN and CaMKII delta were mapped using pull-down experiments, mutagenesis, ELISA, and structural homology modeling. Ex vivo actions were tested in Langendorff hearts and effects on Ca2+ homeostasis examined by fluorescence (fluo-4) and patchclamp recordings in isolated cardiomyocytes. RESULTS: SN levels were elevated in patients with CPVT and following ventricular arrhythmia-induced cardiac arrest. In contrast to NT-proBNP (N-terminal proB- type natriuretic peptide) and hs-TnT (high-sensitivity troponin T), circulating SN levels declined after resuscitation, as the risk of a new arrhythmia waned. Myocardial pro-SN expression was also increased in CPVT mice, and further adeno-associated virus-9-induced overexpression of SN attenuated arrhythmic induction during stress testing with isoproterenol. Mechanistic studies mapped SN binding to the substrate binding site in the catalytic region of CaMKII delta. Accordingly, SN attenuated isoproterenol induced autophosphorylation of Thr287-CaMKII delta in Langendorff hearts and inhibited CaMKII delta-dependent RyR phosphorylation. In line with CaMKII delta and RyR inhibition, SN treatment decreased Ca2+ spark frequency and dimensions in cardiomyocytes during isoproterenol challenge, and reduced the incidence of Ca2+ waves, delayed afterdepolarizations, and spontaneous action potentials. SN treatment also lowered the incidence of early afterdepolarizations during isoproterenol; an effect paralleled by reduced magnitude of L-type Ca2+ current. CONCLUSIONS: SN production is upregulated in conditions with cardiomyocyte Ca2+ dysregulation and offers compensatory protection against cardiomyocyte mechanisms of arrhythmia, which may underlie its putative use as a biomarker in at-risk patients.
Subject: calcium
calmodulin
heart failure
secretoneurin
tachycardia
PROGNOSTIC VALUE
BRAIN-INJURY
FAILURE
SHOCK
MICE
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
CIRCEP.118.007045.pdf 1.260Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record